- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Inflammasome.
Displaying page 1 of 1.
EudraCT Number: 2015-004292-69 | Sponsor Protocol Number: MEFV01 | Start Date*: 2016-01-12 |
Sponsor Name:UZ Leuven | ||
Full Title: Anakinra (Kineret®) for a hereditary autoinflammatory disease with MEFV mutation and inflammasome activation. | ||
Medical condition: hereditary autoinflammatory disease with MEFV mutation and inflammasome activation | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001455-40 | Sponsor Protocol Number: GRECCO-19 | Start Date*: 2020-04-01 | |||||||||||
Sponsor Name:Hellenic Society of Rhythmology | |||||||||||||
Full Title: The Greek study in the Effects of Colchicine in Covid-19 complications prevention | |||||||||||||
Medical condition: This trial will investigate if colchicine could potentially have an effect in patients’ clinical course by limiting the myocardial necrosis and pneumonia development in the context of COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000233-73 | Sponsor Protocol Number: HCQvJan11 | Start Date*: 2016-01-05 |
Sponsor Name:Helsinki University Central Hospital | ||
Full Title: HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME: PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS | ||
Medical condition: Cardiovascular disease | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004596-31 | Sponsor Protocol Number: NL62772 | Start Date*: 2019-03-25 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass | ||||||||||||||||||
Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002399-28 | Sponsor Protocol Number: RAP-ALS | Start Date*: 2017-07-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA | |||||||||||||
Full Title: Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis | |||||||||||||
Medical condition: definite or probable ALS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002612-31 | Sponsor Protocol Number: MANTICO | Start Date*: 2021-05-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005804-27 | Sponsor Protocol Number: 15-200 | Start Date*: 2016-06-04 | |||||||||||
Sponsor Name:CHU CAEN | |||||||||||||
Full Title: Essai randomisé, contrôlé, en double aveugle, de l'anakinra contre placebo, en adjonction à la corticothérapie dans l'artérite à cellules géantes. | |||||||||||||
Medical condition: Patients atteints d’artérite à cellules géantes (ou maladie de Horton) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003204-13 | Sponsor Protocol Number: 74527 | Start Date*: 2021-11-15 |
Sponsor Name:Radboudumc | ||
Full Title: Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia | ||
Medical condition: Candidemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
